Meeting
2024 ASCO Genitourinary Cancers Symposium
Clonal hematopoiesis of indeterminate potential (CHIP) and cardiovascular toxicity from androgen deprivation therapy in men with prostate cancer.
Authors
Sagar A. Patel
Department of Radiation Oncology, Emory University, Atlanta, GA
Sagar A. Patel , Angelo Marra , Jeffrey M. Switchenko , H. Richard Johnston , Lyra M. Griffiths , Avirup Guha , Stephanie M. Cantu , Mylin Ann Torres , Ashesh B. Jani , Anant Mandawat
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 312)
DOI
10.1200/JCO.2024.42.4_suppl.312
Abstract #
312
Poster Bd #
N3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Germline mutations and the presence of clonal hematopoiesis of indeterminate potential (CHIP) in 20,963 patients with BRCA-associated cancers.
First Author: Catherine Handy Marshall
Poster
2024 ASCO Genitourinary Cancers Symposium
Relugolix versus leuprolide in combination with radiotherapy for localized prostate cancer (REVELUTION trial): An initial analysis of patient treatment preferences and quality of life.
First Author: Sagar A. Patel
Poster
2023 ASCO Annual Meeting
Clonal hematopoiesis in the phase 3 Alliance A031201 trial of metastatic castration resistant prostate cancer (mCRPC) treated with androgen receptor (AR)-targeted therapies.
First Author: Jeffrey Lee Jensen
Poster
2023 ASCO Annual Meeting
Outcomes of individuals with clonal hematopoiesis evaluated at a cancer center.
First Author: Kelly Sharon Chien